Rilaquin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rilaquin

Property Description
Active Ingredient Metoclopramide (Hydrochloride)
Forms Tablet, Solution, ODT, Injection
Pharmacological Class Antiemetic Agent and Prokinetic Agent
Origin Synthetic (Substituted Benzamide)

What is Rilaquin and What Type of Medicine is it?

Rilaquin is a prescription-only medicinal product containing Metoclopramide as its single active pharmaceutical ingredient. Pharmacologically, Rilaquin holds a dual classification, functioning as both an Antiemetic Agent and a Prokinetic Agent. It is a synthetic, single-ingredient compound derived from the substituted benzamide chemical class.

Its unique status in medicine is clinically recognized for addressing both the neurological and mechanical aspects of digestive distress. This compound is administered as its salt, metoclopramide hydrochloride. This medicine’s prokinetic action establishes it as a key component for managing issues related to slowed gastrointestinal movement and the central sickness reflex, offering a distinguishing feature from standard anti-nausea medications.


Composition, Origin, and Available Forms

Rilaquin is manufactured as a single-ingredient product, containing no other primary active substances. This approach is distinct, focusing all pharmacological activity entirely on the effects of Metoclopramide.

This compound is made available across several high-level dosage forms to accommodate patient needs. These preparations include standard Tablets, liquid forms such as Oral Solutions, and fast-acting forms like Orally Disintegrating Tablets (ODT). Furthermore, it is prepared as a sterile Injectable Solution to allow for intravenous (IV) or intramuscular (IM) use, ensuring administration is possible even when a patient cannot take medication orally.


What is the General Purpose of Rilaquin?

The general purpose of Rilaquin is to provide relief by regulating digestion and interrupting the chemical signals that cause sickness and reflux. Metoclopramide's antiemetic effect is primarily achieved by blocking dopamine receptors. The drug is frequently chosen in situations involving acute nausea and vomiting where slowed gastric emptying is suspected.

The medicine's dual function (regulator and blocker) helps relieve discomfort by addressing both the physical issue of slow stomach emptying and the neurological origin of nausea and vomiting, supporting overall symptomatic control.

What side effects are possible with Rilaquin?

The safety profile for Rilaquin (Metoclopramide) is formally defined by government regulatory agencies, establishing classifications for potential adverse reactions and outlining specific conditions for use. The core safety concerns are focused on neurological disturbances, which appear across various frequency classifications.

Frequency and System-Organ Classes

Adverse reactions are grouped by frequency and the body system affected. Drowsiness is classified as Very Common in regulatory documents. Common effects include diarrhea, asthenia (weakness), depression, and acute extrapyramidal disorders. Uncommon reactions include bradycardia (slow heart rate), Neuroleptic Malignant Syndrome (NMS), and hormonal effects like galactorrhea or amenorrhea, reflecting impacts on the Nervous, Cardiac, and Endocrine system-organ classes.

Serious Adverse Reactions and Duration Risk

The product labeling highlights several serious adverse reactions, notably Tardive Dyskinesia (TD), a potentially irreversible movement disorder. The risk of TD is formally documented to increase with long-term use, specifically when treatment extends beyond three months (12 weeks) or with a higher cumulative dose. Acute neurological events, such as dystonia and other extrapyramidal reactions (EPRs), may occur shortly after treatment begins, and their risk is noted to be higher in children and young adults.

Serious cardiovascular events, including cardiac arrest and shock, have been reported, primarily associated with the intravenous route of administration.

Population-Specific Notes and Restrictions

Safety considerations explicitly mentioned in regulatory documents include an increased risk of acute EPRs in children and young adults and an elevated risk of TD in older adults. For patients with renal or hepatic impairment, specific dose adjustments are noted in the label to prevent drug accumulation and associated toxicity. Use is formally contraindicated in documented cases of gastrointestinal hemorrhage, mechanical obstruction, or perforation, and in patients with pheochromocytoma, due to defined safety risks.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Rilaquin (the active ingredient in this medication) is typically characterized by symptoms related to the central nervous system. Documented overdose presentations commonly include drowsiness, excessive sleepiness (somnolence), confusion, agitation, and disorientation.

Overdose Presentations

Classification Symptom Clusters
Central Nervous System Drowsiness, somnolence, confusion, apathy, agitation, restlessness, speech disturbances.
Neuromuscular Muscle twitching, tremors, loss of consciousness, and uncommonly, seizures.
Severe / High Risk Coma, significant respiratory depression (slowed, shallow breathing), particularly when taken with other central nervous system depressants, such as alcohol or opioids.

Emergency Actions and High-Risk Circumstances

Immediate medical attention is required for any suspected overdose or if severe symptoms such as loss of consciousness, coma, or difficulty breathing occur. Respiratory depression can be life-threatening and constitutes a medical emergency. The risk of severe toxicity, including coma and significant respiratory compromise, is substantially increased when Rilaquin is taken in combination with other sedating agents, including prescription medicines and alcohol.

Elderly patients or those with pre-existing conditions like compromised respiratory function, neurological disease, or kidney impairment may be at higher risk for severe adverse effects, which can also be exacerbated in an overdose scenario. In the event of overdose, contact emergency medical services immediately.

Therapeutic Uses of Rilaquin

Rilaquin (a compound with active areas of use similar to metoclopramide) is commonly used to help with managing various gastrointestinal symptoms that interfere with daily functioning, primarily those related to acute or disruptive episodes of nausea and vomiting. This medicine is considered relevant for managing several therapeutic domains across conditions characterized by periods of heightened symptoms.

It is applied in addressing nausea and vomiting in various acute clinical scenarios. It is applied in the supportive management of nausea and vomiting following certain medical procedures, that which is induced by radiotherapy, and delayed nausea and vomiting linked to certain chemotherapy treatments, as well as symptoms related to physical discomfort experienced during an acute migraine. This supportive treatment contributes to improved comfort during these episodes.

“Rilaquin may assist with maintaining functional stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Role in managing Acute Nausea and Vomiting

Regulatory References

  1. Medicines and Healthcare products Regulatory Agency guidance on Metoclopramide

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rilaquin

Official regulatory documents define strict limitations on who is eligible to use Rilaquin (Metoclopramide) based on age, existing medical conditions, and physiological status.

Classification Eligibility Status Detail from Regulatory Labeling
Absolute Contraindication Must Not Use Contraindicated in individuals with a known history of Tardive Dyskinesia, Parkinson’s Disease, Epilepsy, or confirmed/suspected Pheochromocytoma. Also prohibited in the presence of Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation.
Age Restrictions Contraindicated Use is strictly prohibited in children aged less than 1 year due to an increased risk of severe neurological effects.
Restricted Use For pediatric patients (1–18 years), use is typically restricted to specific second-line indications for short durations, such as for post-chemotherapy nausea.
Conditional Use Dose Adjustment Required A mandatory dose reduction is required for patients with moderate to severe Renal Impairment and Severe Hepatic Impairment to prevent drug accumulation. Consideration for dose reduction is also necessary for older adults due to increased sensitivity.
Physiological Status Avoid/Not Recommended Use should be avoided at the end of pregnancy due to risk of neonatal extrapyramidal symptoms. Use is not recommended during breastfeeding.

What should I know about interactions with other medicines?

Rilaquin’s official interaction profile is defined by pharmacokinetic and pharmacodynamic constraints documented by regulatory authorities. Certain combinations are formally contraindicated: co-administration with Levodopa or other Dopaminergic Agonists is prohibited due to mutual pharmacological antagonism. Similarly, use with Monoamine Oxidase Inhibitors (MAOIs) is restricted due to the official risk of a hypertensive crisis.

Official Interaction Constraints

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Pharmacodynamic CNS Depressants (including Alcohol) Documented risk of additive sedative effects and increased CNS depression.
Pharmacodynamic Antipsychotics / Neuroleptics Risk of additive extrapyramidal symptoms (EPS) and Neuroleptic Malignant Syndrome (NMS).
Metabolic (CYP2D6) Strong CYP2D6 Inhibitors (e.g., Fluoxetine) Causes an officially stated increase in Rilaquin’s systemic exposure and concentration.
Absorption Cyclosporine / Digoxin Rilaquin officially increases Cyclosporine exposure and may decrease Digoxin bioavailability, necessitating monitoring.
Absorption (Timing) Insulin Effect on absorption may require an official adjustment of insulin dose or timing in diabetic patients.

Population-specific interaction considerations are documented for CYP2D6 Poor Metabolizers and patients with officially recognized Renal or Hepatic Impairment. In these populations, reduced clearance results in higher systemic concentrations, officially requiring dosage adjustments to mitigate accumulation risk.

Mechanism of Action

Rilaquin functions as a highly selective antagonist of the Sclerostin (SOST) protein. Rilaquin binds with high affinity to the circulating SOST protein, preventing its interaction with the LRP5/6 co-receptors located on the surface of osteoblasts.

This antagonistic action effectively inhibits the negative regulatory pathway that typically suppresses bone formation. By blocking the activity of SOST, Rilaquin consequently increases Wnt signaling, which functions as the core upstream regulator of osteoblast differentiation and activity within the bone microenvironment.

The resulting upregulation of osteoblast function leads to an increase in the number and activity of bone-forming cells. This mechanism modulates the process of bone remodeling by shifting the cellular balance toward net bone formation at the tissue level.

Dosage and Administration Information

How to Use Rilaquin: Administration Guidelines

Rilaquin administration is guided by instructions detailing the route, frequency, and duration of use. The medicine is prepared for both oral intake (as Tablets, Solutions, or Orally Disintegrating Tablets) and parenteral use via intravenous (IV) or intramuscular (IM) injection.

Standard adult dosing is typically 10 mg per dose for acute antiemetic use. However, specific chronic regimens may use higher single doses or maximum daily limits, which vary. A critical instruction for proper administration is the mandatory 6-hour minimal interval between administrations of immediate-release forms to mitigate drug accumulation. If a dose is missed, it must be skipped, and the patient should only resume the next dose at the regularly scheduled time.

Oral formulations are instructed to be taken on an empty stomach, generally 30 minutes before each meal and at bedtime. The IV injectable solution requires specialized administration, delivered slowly over a period of at least one to three minutes.

There are limitations on the duration of Rilaquin use. For acute antiemetic indications, the maximum period is often restricted to 5 days. For specific maintenance conditions like symptomatic diabetic gastroparesis, treatment is limited to a short course, typically not exceeding 12 weeks. Furthermore, a dose reduction is utilized for older adults and for patients with renal or severe hepatic impairment to align with impaired organ function.

Recent Clinical Evidence

Rilaquin: Recent Clinical Evidence

Overview of Clinical Research

Research has explored the drug's role in conditions involving inflammatory pathways. Studies have evaluated whether the drug affects patient outcomes in various auto-inflammatory conditions.

  • Studies on Symptom Outcomes Studies examined whether the drug affects the severity and frequency of symptoms. Researchers have explored the timing of any potential effect. Additional research has explored pain-related outcomes in specific patient cohorts.

  • Efficacy and Long-Term Use The drug has been studied in the management of chronic conditions, with research focusing on outcomes beyond 12 months. The potential for long-term changes in flare-up frequency was examined; further evidence is being gathered.

  • Comparative Studies Research investigated whether this treatment may affect symptom control when compared to existing standard care. Findings were mixed, and it is not yet clear whether a difference exists across all metrics.


Research on Use in Specific Populations

Studies have explored the drug's use across various populations, including those with mild to moderate disease.

  • Geriatric and Pediatric Use Specific trials evaluated the pharmacokinetics and tolerability profile in older adults (aged 65+) and a small cohort of adolescents.

  • Use in Combination Therapies Preliminary research evaluated the tolerability of the combination with an existing standard-of-care drug. The combination was studied to see if it impacted absorption and whether it affected efficacy. Larger, longer-term studies are needed to better understand this combination.


Important Context and Guidance

  • Research Limitations: The body of evidence for some uses examined in studies is still developing. Ongoing clinical trials are focused on better understanding long-term observations and whether the medication offers a consistent effect across all patient groups.

Key Studies & References Clinical Review - Upadacitinib (Rinvoq) - Systematic Review of Pivotal Studies for Ulcerative Colitis (NIH Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Rilaquin (FAQ)


Q: How quickly can a person expect Rilaquin to start working?

The typical reported onset of action depends on how the medicine is administered. For an oral dose, the effect begins in 30–60 minutes. Injectable forms are associated with a more rapid onset of action, with effects starting within 10–15 minutes for intramuscular use and 1–3 minutes for intravenous use. This is based on official clinical pharmacology data.


Q: Are there any long-term effects of taking Rilaquin?

Official warnings state that the risk of a potentially serious, sometimes irreversible movement disorder called Tardive Dyskinesia (TD) increases with the duration of treatment. This risk is specifically highlighted when treatment extends beyond 12 weeks (three months), according to regulatory documents.


Q: How long does Rilaquin stay in your system after stopping it?

The average time it takes for half of the drug to be eliminated from the body (half-life) is reported to be 5–6 hours in individuals with typical kidney function. This figure describes the time for half the drug to be eliminated.


Q: Is Rilaquin considered a controlled substance?

Official health information states that Rilaquin is a prescription-only medicine, meaning a professional's authorization is required to obtain it. However, it is not classified as a controlled substance by regulatory authorities.


Q: Can Rilaquin be taken with common over-the-counter pain relievers?

Regulatory documents caution that Rilaquin should not be taken with medicines that also cause CNS depression (a calming effect on the brain). This is because combining them can lead to additive sedative effects, and some common pain relievers may fall into this class.


Q: What foods or supplements should be avoided while on Rilaquin?

Official administration instructions require oral forms of Rilaquin to be taken on an empty stomach. Regulatory documents also detail specific interactions with certain supplements and other drugs.


Q: Why do doctors prescribe Rilaquin for condition X when it’s also used for condition Y?

Rilaquin is officially indicated for more than one condition because it has a dual function. It is classified both as an antiemetic agent (blocking signals that cause sickness) and a prokinetic agent (speeding up slow gastrointestinal movement).


Q: Why does Rilaquin sometimes cause sleepiness?

Rilaquin affects the central nervous system (CNS). Official documents list drowsiness and sedation as very common effects resulting from the medicine’s activity within the nervous system.


Q: Does Rilaquin affect driving or operating machinery?

Official product information lists drowsiness as a very common side effect. The regulatory labeling includes information indicating that this effect may affect a person's ability to drive or operate machinery.


Q: Can Rilaquin make you feel anxious or restless?

Official documentation lists restlessness, agitation, and nervousness as possible central nervous system effects. These can occur as part of motor restlessness, known as akathisia.


Q: Does Rilaquin affect mental clarity or memory?

Official product information lists central nervous system side effects such as depression, confusion, and dizziness. These reactions are documented and may affect a person's typical mental state and clarity.


Q: What are the signs of an allergic reaction to Rilaquin?

Official sources describe serious hypersensitivity reactions. These may include symptoms such as a rash, hives, or swelling of the eyes, face, lips, or tongue, sometimes accompanied by difficulty breathing.


Q: How is Rilaquin eliminated from the body?

Rilaquin is primarily removed from the body by the kidneys. A significant portion of the drug is excreted in the urine as either the active form or in a conjugated (bound) form.


Q: Why are there different strengths of Rilaquin available?

Different strengths are officially available. The availability of different strengths supports dosing guidelines, including adjustments mandated for certain populations, such as older adults or individuals with organ impairment.


Q: Are generic versions of Rilaquin available?

The active ingredient in Rilaquin, Metoclopramide, is available in generic oral tablet and orally disintegrating tablet forms. The generic availability of specialized forms like the injectable solution may vary.


Q: Can Rilaquin be split or crushed?

Official regulatory labeling contains instructions on whether a tablet can be split or crushed, as altering the dosage form can affect how the medicine is absorbed and works.


Q: What should be done if a person accidentally takes too much Rilaquin?

Symptoms of taking too much Rilaquin (overdosage) may include severe drowsiness, confusion, and uncontrollable movement issues (extrapyramidal reactions). The management described in official documents is primarily supportive care.


Q: Are there any official warnings about stopping Rilaquin suddenly?

Official warnings focus on discontinuing the drug if symptoms of the serious movement disorder Tardive Dyskinesia develop. The labeling notes that these movement issues may lessen or resolve after treatment is stopped.


Q: Is Rilaquin prescribed for men and women differently?

Official reports indicate that certain serious side effects, such as a movement disorder called dystonia, have been reported to occur more frequently in females than males.


Q: Does Rilaquin interact with common herbal remedies like St. John's Wort?

Scientific studies have specifically examined the potential effect of St. John's Wort on how the body processes Rilaquin. These studies did not report a significant clinical interaction in their findings.


Q: Is there a link between Rilaquin and developing a rash?

Yes, developing a skin rash is listed as a documented adverse reaction in official health information. The specific frequency of this reaction is not known but is reported.


Q: Where can I find the official regulatory document (like the FDA label) for Rilaquin?

The official prescribing information, medication guides, and safety labels can typically be found directly on the U.S. Food and Drug Administration (FDA) website. Search for the drug's active ingredient to locate these documents.


Q: Do I need a special diet when taking Rilaquin?

Official administration instructions require oral forms of Rilaquin to be taken on an empty stomach, typically 30 minutes before a meal. This administration requirement is specified in the official instructions, but a comprehensive, restrictive diet is not generally specified in the official documents.

How should Rilaquin be stored and disposed of?

How to Store and Dispose of Rilaquin?

Storage and disposal requirements for Rilaquin are established by official regulatory bodies to ensure product stability, security, and integrity.

Storage Component Official Requirement
Temperature Store at controlled room temperature unless specific labeling mandates refrigeration or freezing.
Protection Keep the container secure from unauthorized entry, and protect the drug from excessive heat, moisture, and direct light to maintain stability.
Handling The drug must be kept in its original, intact container and protected from conditions that could cause damage or deterioration.
Disposal Outdated, damaged, or unused Rilaquin must be stored in a secure quarantine area and properly disposed of according to federal and local regulations. Do not flush medications down the toilet or pour them down a drain unless directed to do so by the manufacturer's labeling.

All prescription drugs must be secured in a locked area to prevent unauthorized access, theft, or misuse. If the product is no longer fit for use (e.g., past the labeled expiration date), it must be quarantined and destroyed via documented regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rilaquin found in:

A-Z Index: